Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1119 in Solid Tumors
NCT07695831Phase 1Recruiting
- Sponsor
- Genmab
- Start
- Aug 2026
- Primary completion
- Jun 2029
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of GEN1119 in solid tumor (3 arms), sponsored by Genmab. Primary endpoints: Dose-limiting Toxicities at 21 days, Adverse Events at 17.5 months and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
GEN1119
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07695831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695831.